How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,546 results for

Pharmacologic Stress Test

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder

Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder: Groundwork for a Publicly Available Repository of Randomized Controlled Trial Data Technical Brief Number 32 R Technical Brief Number 32 Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder: Groundwork for a Publicly Available Repository of Randomized Controlled Trial Data Prepared for: Agency for Healthcare (...) -EHC018-EF May 2019 ii Key Messages Purpose The purpose of this project was to identify and abstract data from randomized controlled trials (RCTs) of posttraumatic stress disorder (PTSD) interventions to support the development of a publicly accessible data repository by the National Center for Posttraumatic Stress Disorder. Key Messages • We abstracted data from 318 RCTs, including psychotherapeutic interventions (55%), pharmacologic interventions (30%), and complementary and integrative

2019 Effective Health Care Program (AHRQ)

2. Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update

Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE In partnership with Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update MAY 2018Comparative Effectiveness Review Number 207 Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update Prepared for: Agency (...) and strength of evidence of PTSD psychological treatments ES-3 Table C. Summary of efficacy and strength of evidence of PTSD pharmacological treatments ES-5 Table D. Summary of review characteristics ES-9 Table 1. Diagnostic criteria for posttraumatic stress disorder 2 Table 2. Inclusion/exclusion criteria for psychological and pharmacological treatments for adults with posttraumatic stress disorder 9 Table 3. Definitions of the grades of overall strength of evidence 14 Table 4. Outcome measure tools

2018 Effective Health Care Program (AHRQ)

3. Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome

Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Arm Exercise (...) Versus Pharmacologic Stress Testing for Clinical Outcome (ArmCrank) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03449888 Recruitment Status : Recruiting First Posted : February 28, 2018 Last Update Posted : December 28

2018 Clinical Trials

4. A physiologist observing and reporting supra-pharmacologic dobutamine stress testing: can we trust them, and can we trust the results? Full Text available with Trip Pro

A physiologist observing and reporting supra-pharmacologic dobutamine stress testing: can we trust them, and can we trust the results? In a study, published in this issue of Echo Research and Practice, Ntoskas et al retrospectively analyzed the safety of a cardiac physiologist performing, and interpreting, Dobutamine stress echocardiography (DSE) in of 300 patients undergoing DSE for the detection of inducible reversible ischemia, myocardial viability and valvular heart disease. While safety (...) during the tests themselves did not appear to be compromised with this unsupervised approach, the interpretation of these DSEs causes concerns regarding broad patient safety relative to misread results.© 2018 The authors.

2018 Echo research and practice

5. General medicine: Prevention of exacerbations in patients with stable non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis of pharmacological and non-pharmacological therapies Full Text available with Trip Pro

General medicine: Prevention of exacerbations in patients with stable non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis of pharmacological and non-pharmacological therapies Prevention of exacerbations in patients with stable non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis of pharmacological and non-pharmacological therapies | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You (...) of exacerbations in patients with stable non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis of pharmacological and non-pharmacological therapies Article Text Evidence synthesis General medicine Prevention of exacerbations in patients with stable non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis of pharmacological and non-pharmacological therapies Free Abd Moain Abu Dabrh , , Adam T Hill , Claudia C Dobler , Noor Asi , Wigdan H Farah , Qusay Haydour , Zhen Wang

2018 Evidence-Based Medicine

6. Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder: Investigation of Placebo Response in a Pharmacological Treatment Study of Post-Traumatic Stress Disorder. Full Text available with Trip Pro

Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder: Investigation of Placebo Response in a Pharmacological Treatment Study of Post-Traumatic Stress Disorder. For a drug to acquire Food and Drug Administration approval, it must significantly outperform placebo treatment. In recent years, the placebo effect seems to be increasing in neuropsychiatric conditions. Here, we examine placebo effects across self-reported (...) , clinically rated, and performance-based data from a trial using a corticotropin-releasing hormone receptor type 1 (CRHR1) antagonist for treatment of post-traumatic stress disorder (PTSD).Women with chronic PTSD were randomized to treatment with either GSK561679, a CRHR1 antagonist, or placebo. Before randomization, participants completed self-report scales, clinician-rated measures of PTSD and depression symptoms, and objective tests of cognition and functioning. Differences in change scores on measures

2018 Journal of Clinical Psychopharmacology Controlled trial quality: uncertain

7. Pharmacologic Stress Test

Pharmacologic Stress Test Pharmacologic Stress Test Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Pharmacologic Stress Test (...) Pharmacologic Stress Test Aka: Pharmacologic Stress Test , Stress Imaging with Pharmacologic Provocation II. Indications Cardiac Screening in patients unable to 5 Mets Intermediate pretest risk of CAD III. Tests No s for 24 hours before test Avoid if very large body habitus (poor echo window) Definity or optison contrast can be used to increase accuracy (or Regadenoson/Lexiscan) Avoid in severe , , No nitrates on day of test No s (e.g. ) for 24 hours prior Myocardial Perfusion Imaging with Uses ( ) instead

2018 FP Notebook

8. Exercise and pharmacologic stress-induced interlead T-wave heterogeneity analysis to detect clinically significant coronary artery stenosis. Full Text available with Trip Pro

Exercise and pharmacologic stress-induced interlead T-wave heterogeneity analysis to detect clinically significant coronary artery stenosis. Despite widespread use of ETT and vasodilator-stress with myocardial perfusion imaging (MPI) for noninvasive detection of flow-limiting coronary artery disease, there is continued need to improve diagnostic accuracy. We examined whether measurement of interlead T-wave heterogeneity (TWH) during exercise tolerance testing (ETT) or pharmacologic stress (...) . By contrast, neither ST-segment changes during ETT (p = 0.12) nor MPI during dipyridamole stress testing (p = 0.60) discriminated cases from controls.TWH measurement is a novel method that improves detection of angiographically confirmed flow-limiting stenoses in large epicardial coronary arteries during both ETT and MPI during pharmacologic stress testing with dipyridamole.Copyright © 2019 Elsevier B.V. All rights reserved.

2019 International journal of cardiology

9. Identification of a pharmacological inhibitor of Epac1 that protects the heart against acute and chronic models of cardiac stress. (Abstract)

Identification of a pharmacological inhibitor of Epac1 that protects the heart against acute and chronic models of cardiac stress. Recent studies reported that cAMP-binding protein Epac1-deficient mice were protected against various forms of cardiac stress, suggesting that pharmacological inhibition of Epac1 could be beneficial for the treatment of cardiac diseases. To test this assumption, we characterized an Epac1-selective inhibitory compound and investigated its potential cardioprotective

2019 Cardiovascular Research

10. Effects of non-pharmacological stress and/or anxiety reduction or prevention interventions delivered to women and their partners from conception to 2 years postpartum (the first 1000 days) on stress and anxiety

Effects of non-pharmacological stress and/or anxiety reduction or prevention interventions delivered to women and their partners from conception to 2 years postpartum (the first 1000 days) on stress and anxiety Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD (...) : Whenever a control group serves more than one experimental group, we will correct the total number of control animals in the meta-analysis by dividing the number of animals in the control group by the number of treatment groups served. Where applicable, Holm-Bonferroni correction for testing multiple subgroup analyses will be performed. If one or more subgroup analyses cannot be performed due to insufficient data, the p-value will be adjusted accordingly. ">Other Subgroup analysis or meta-regression

2019 PROSPERO

11. Haemodynamic effects of pharmacologic stress with adenosine in patients with left ventricular systolic dysfunction. (Abstract)

Haemodynamic effects of pharmacologic stress with adenosine in patients with left ventricular systolic dysfunction. In patients with heart failure, downregulation of adenosine receptor gene expression and impaired adenosine-related signal transduction may result in a diminished response to adenosine. This may have implications for cardiac stress testing. We evaluated the haemodynamic response to intravenous adenosine in patients with left ventricular systolic dysfunction (LVSD) undergoing (...) stress cardiovascular magnetic resonance imaging (CMR).We retrospectively examined 497 consecutive patients referred for clinical stress CMR. Blood pressure and heart rate responses with intravenous adenosine were compared in patients with normal, mild-moderately impaired and severely impaired LV systolic function (ejection fraction [EF] > 55%, 36-55% and < 35%, respectively). Following 2 min of adenosine infusion, there was a significant difference between the groups in the heart rate change from

2018 International journal of cardiology

12. The social defeat/overcrowding murine psychosocial stress model results in a pharmacologically reversible body weight gain but not depression - related behaviours Full Text available with Trip Pro

The social defeat/overcrowding murine psychosocial stress model results in a pharmacologically reversible body weight gain but not depression - related behaviours Depression is a highly prevalent psychiatric disorder, yet its etiology is not well understood. The validation of animal models is therefore a critical step towards advancing knowledge about the neurobiology of depression. Psychosocial stress has been promoted as a prospective animal model of depression, however, different protocols (...) drug treatment. Fluoxetine reduced the number of defeat postures during fight bouts on some days. SD/OC otherwise failed to elicit depression- or anxiety-like behaviour in the tests measured. These data raise questions over the SD/OC model as an etiological model of depression-related behaviours but highlight the potential of this model for investigations into mechanisms regulating binge eating and weight gain under conditions of chronic social stress.

2018 Neurobiology of stress

13. Stress alters social behavior and sensitivity to pharmacological activation of kappa opioid receptors in an age-specific manner in Sprague Dawley rats Full Text available with Trip Pro

Stress alters social behavior and sensitivity to pharmacological activation of kappa opioid receptors in an age-specific manner in Sprague Dawley rats The dynorphin/kappa opioid receptor (DYN/KOR) system has been identified as a primary target of stress due to behavioral effects, such as dysphoria, aversion, and anxiety-like alterations that result from activation of this system. Numerous adaptations in the DYN/KOR system have also been identified in response to stress. However, whereas most (...) studies examining the function of the DYN/KOR system have been conducted in adult rodents, there is growing evidence suggesting that this system is ontogenetically regulated. Likewise, the outcome of exposure to stress also differs across ontogeny. Based on these developmental similarities, the objective of this study was to systematically test effects of a selective KOR agonist, U-62066, on various aspects of social behavior across ontogeny in non-stressed male and female rats as well as in males

2018 Neurobiology of stress

14. Early pharmacological interventions for preventing post-traumatic stress disorder (PTSD): a network meta-analysis [Cochrane protocol]

Early pharmacological interventions for preventing post-traumatic stress disorder (PTSD): a network meta-analysis [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record (...) experimental group, we will correct the total number of control animals in the meta-analysis by dividing the number of animals in the control group by the number of treatment groups served. Where applicable, Holm-Bonferroni correction for testing multiple subgroup analyses will be performed. If one or more subgroup analyses cannot be performed due to insufficient data, the p-value will be adjusted accordingly. ">Other Subgroup analysis or meta-regression are used to explore between-study heterogeneity

2020 PROSPERO

15. Pharmacological Treatment of Children and Adolescents with Post-Traumatic Stress Disorder: A Systematic Review

Pharmacological Treatment of Children and Adolescents with Post-Traumatic Stress Disorder: A Systematic Review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) animals in the meta-analysis by dividing the number of animals in the control group by the number of treatment groups served. Where applicable, Holm-Bonferroni correction for testing multiple subgroup analyses will be performed. If one or more subgroup analyses cannot be performed due to insufficient data, the p-value will be adjusted accordingly. ">Other Subgroup analysis or meta-regression are used to explore between-study heterogeneity and can provide insight into the relationship between study

2020 PROSPERO

16. The efficacy of psychotherapy and pharmacological for Posttraumatic Stress Disorder: A meta-analysis of Randomized Controlled Trials

The efficacy of psychotherapy and pharmacological for Posttraumatic Stress Disorder: A meta-analysis of Randomized Controlled Trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record (...) experimental group, we will correct the total number of control animals in the meta-analysis by dividing the number of animals in the control group by the number of treatment groups served. Where applicable, Holm-Bonferroni correction for testing multiple subgroup analyses will be performed. If one or more subgroup analyses cannot be performed due to insufficient data, the p-value will be adjusted accordingly. ">Other Subgroup analysis or meta-regression are used to explore between-study heterogeneity

2020 PROSPERO

17. Nonopioid Pharmacologic Treatments for Chronic Pain

=019872. Accessed July 31, 2019. 11. Acetaminophen. https://www.drugs.com/monograph/acetami nophen.html. Accessed July 31, 2019. 12. Kansagara D, O'Neil M, Nugent S, et al. VA Evidence-based Synthesis Program Reports. Benefits and Harms of Cannabis in Chronic Pain or Post-traumatic Stress Disorder: A Systematic Review. Washington, DC: Department of Veterans Affairs (US); 2017. 13. Bannuru RR, Schmid CH, Kent DM, et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis (...) Nonopioid Pharmacologic Treatments for Chronic Pain Nonopioid Pharmacologic Treatments for Chronic Pain Comparative Effectiveness Review Number 228 R Comparative Effectiveness Review Number 228 Nonopioid Pharmacologic Treatments for Chronic Pain Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-00009-I Prepared by: Pacific Northwest Evidence-based Practice Center Portland

2020 Effective Health Care Program (AHRQ)

18. Haemodynamic changes during physiological and pharmacological stress testing. A systematic review

Haemodynamic changes during physiological and pharmacological stress testing. A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address (...) models Example: Heterogeneity will be assessed using the (residual) I2 and adjusted R2 statistics. ">Heterogeneity For further guidance please refer to the and to pre-clinical meta-analysis. Example: Whenever a control group serves more than one experimental group, we will correct the total number of control animals in the meta-analysis by dividing the number of animals in the control group by the number of treatment groups served. Where applicable, Holm-Bonferroni correction for testing multiple

2017 PROSPERO

19. Pharmacological management of migraine

Pharmacological management of migraine SIGN 155 • Pharmacological management of migraine A national clinical guideline February 2018 Evidence www.healthcareimprovementscotland.org Edinburgh Office | Gyle Square |1 South Gyle Crescent | Edinburgh | EH12 9EB Telephone 0131 623 4300 Fax 0131 623 4299 Glasgow Office | Delta House | 50 West Nile Street | Glasgow | G1 2NP Telephone 0141 225 6999 Fax 0141 248 3776 The Healthcare Environment Inspectorate, the Scottish Health Council, the Scottish (...) and Diversity Officer. Every care is taken to ensure that this publication is correct in every detail at the time of publication. However, in the event of errors or omissions corrections will be published in the web version of this document, which is the definitive version at all times. This version can be found on our web site www.sign.ac.uk. This document is produced from elemental chlorine-free material and is sourced from sustainable forests.Scottish Intercollegiate Guidelines Network Pharmacological

2018 SIGN

20. Pharmacological Management of Osteoporosis in Postmenopausal Women Full Text available with Trip Pro

Pharmacological Management of Osteoporosis in Postmenopausal Women We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite (...) Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation May 2019 Article Contents Article Navigation Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline Richard Eastell University of Sheffield, Sheffield, United Kingdom Search for other works by this author on: Clifford J Rosen Maine Medical Center Research Institute, Scarborough, Maine Correspondence: Clifford J. Rosen, MD

2019 The Endocrine Society

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>